Cancer screening campaigns - Getting past uninformative persuasion

New England Journal of Medicine

Volumn 367, Issue 18, 2012, Pages 1677-1679

  Woloshin, Steven ^a,b,c   Schwartz, Lisa M ^a,b,c   Black, William C ^c,d   Kramer, Barnett S ^e  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c NORRIS COTTON CANCER CENTER   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868230140     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1209407     Document Type: Article

References (5)

1. Lerner BH. The breast cancer wars. Oxford, United Kingdom: Oxford University Press, 2001.
2. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast and prostate cancer. JAMA 2009;302:1685-92.
3. The National Lung Screening Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
4. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 2009;150:516-27.
5. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.